Shattuck Labs, Inc. - Common Stock (STTK)

Curious to know what's happening on the US markets one hour before the close of the markets on Tuesday? Join us as we explore the top gainers and losers in today's session.

The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

After the closing bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Shattuck Labs shifts focus to SL-325 after modest survival improvements in a Phase 1 trial for HR-MDS and TP53m AML. The company plans workforce reductions and expects cash reserves to last into 2027.

STTK stock results show that Shattuck Labs missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

STTK stock results show that Shattuck Labs beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

A look at five stocks that saw increased interest from Benzinga readers during the week.

Shares of RxSight, Inc. (NASDAQ: RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 revenue guidance above estimates. Also, Needham maintained a Buy rating on the stock and raised its price target from $35 to $41.